Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration

J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155. doi: 10.1111/jgh.15853. Epub 2022 Apr 26.

Abstract

Background and aim: Balloon-occluded retrograde transvenous obliteration (BRTO) is widely performed for treating gastric varices (GVs). However, worsening of esophageal varices (EVs) can be observed after BRTO. This study aimed to investigate the impact of EV worsening on prognosis after BRTO.

Methods: Overall, 258 patients who underwent initial BRTO for GV treatment between January 2004 and May 2019 at 12 institutions were retrospectively registered.

Results: Technical success was achieved in 235 patients (91.1%). Based on the exclusion criteria, 37 patients were excluded, and 198 were evaluated. The cumulative worsening rates of EVs at 1, 2, and 3 years were 39.0%, 59.4%, and 68.4%, respectively. In the univariate Cox proportional hazards model, sex, EV size, history of EV treatment, left gastric vein dilatation, platelet count, aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, albumin-bilirubin score, prothrombin time-international normalized ratio, fibrosis-4 index, AST to platelet ratio index, and spleen width were significantly associated with worsening of EV after BRTO. Multivariate analysis showed that sex (adjusted hazard ratio [aHR] 1.72; 95% confidence interval [CI] 1.03-2.86; P = 0.04), left gastric vein dilatation (aHR 1.90; 95% CI 1.17-3.10; P = 0.01), ALT (aHR 1.01; 95% CI 1.00-1.03; P = 0.02), albumin (aHR 0.61; 95% CI 0.43-0.87; P < 0.01), and spleen width (aHR 1.02; 95% CI 1.01-1.03; P < 0.01) were independent risk factors for worsening of EV after BRTO. Patients with EV worsening within 1 year after BRTO had a significantly worse prognosis than the other patients (P = 0.007).

Conclusions: Early worsening of EV after BRTO was associated with poor prognosis after BRTO.

Keywords: BRTO; gastric varices; liver cirrhosis; portal hypertension; spleen size.

MeSH terms

  • Albumins
  • Balloon Occlusion* / adverse effects
  • Bilirubin
  • Esophageal and Gastric Varices* / etiology
  • Esophageal and Gastric Varices* / therapy
  • Humans
  • Prognosis
  • Treatment Outcome

Substances

  • Albumins
  • Bilirubin